Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models

Propranolol, a pleiotropic β-adrenergic blocker, has been anecdotally reported to reduce cerebral cavernous malformations (CCMs) in humans. However, propranolol has not been rigorously evaluated in animal models, nor has its mechanism of action in CCM been defined. We report that propranolol or its...

詳細記述

保存先:
書誌詳細
出版年:J Clin Invest
主要な著者: Li, Wenqing, Shenkar, Robert, Detter, Mathew R., Moore, Thomas, Benavides, Christian, Lightle, Rhonda, Girard, Romuald, Hobson, Nicholas, Cao, Ying, Li, Yan, Griffin, Erin, Gallione, Carol, Zabramski, Joseph M., Ginsberg, Mark H., Marchuk, Douglas A., Awad, Issam A.
フォーマット: Artigo
言語:Inglês
出版事項: American Society for Clinical Investigation 2021
主題:
Concise Communication
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7843213/
https://ncbi.nlm.nih.gov/pubmed/33301422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI144893
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料